Key facts
- SweetSpot’s last known valuation is $6.5M (Jan 2023).
- It has raised $1.5M.
- Notable investors include Cultivation Capital, BioGenerator Ventures, Arch Grants, Missouri Technology Corporation, CGSTL Group — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for SweetSpot
- ·The full record, as it builds
Funding rounds
No funding rounds for SweetSpot are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SweetSpot
Developer of a diabetes management platform intended to perform monthly data reviews and coordinate with providers and patients to facilitate treatment plan changes. The company combines a centralized software platform for managing diabetes device data, such as data from continuous glucose monitoring (CGM) and insulin pumps, with wrap-around clinical support services, enabling physicians and endocrinologists to ensure patients receive timely treatment adjustments to improve glycemic control and patient outcomes.
- Sector
- Healthcare
- HQ
- Saint Louis, MO, United States
- Founded
- 2020
- Employees
- 5
- Website
- sweetspot.health/
- Ownership
- Privately Held (backing)
SweetSpot doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SweetSpot shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SweetSpot in its N-PORT filings yet. We sweep new filings monthly.